Ilya Pharma first at Testa Center – industrializing its technology for accelerated wound healing

Since the opening of the Testa Center in August, several projects are now underway. First up is Illya Pharma, a spin-out from Uppsala University and the Swedish University of Agricultural Sciences.

– “We have developed modified lactic acid bacteria that act as small bioreactors of therapeutic endogenous proteins directly in wounds on the skin and in the gastrointestinal tract, which speeds up the healing process,” says Evelina Vågesjö, CEO of Ilya Pharma.

In the spring, the final safety studies in large animals were completed and GMP manufacturing will start soon. In parallel, the company will have the opportunity to further verify the manufacturing process at production scale and build valuable industrial knowledge at GE Healthcare’s TestaCenter.

– This has been very important for us and has meant significant risk minimization in the project and that we at an earlier stage have also had the opportunity to industrialize the process for commercial production, says Evelina Vågesjö.

– We have designed the bioprocess ourselves and will keep the process and product know-how within Ilya Pharma. The opportunity to test the phase I production at TestaCenter, and how we imagine it will look like in commercial production, further strengthens our process development,” says Peter Frank, project manager and director drug development at Ilya Pharma.

Top photo: Hava Lofton Tomenius and Peter Frank
Between: Hava Lofton Tomenius and Fredrik Götesson
Bottom: Evelina Vågesjö
Photographer: Martina Sjaunja, Scoopit Media